.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin led to enhanced progression-free and also overall survival, resulting in FDA approval and also a brand new therapy choice for patients.